Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegileridine vs sufentanil for PONV after laparoscopic cholecystectomy
ChiCTR2600125309Phase 4Not yet recruiting
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tegileridine in postoperative nausea and vomiting (PONV), postoperative pain and Gastrointestinal Dysmotility (2 arms), sponsored by First People's Hospital of Lianyungang City. Primary endpoint: Nausea and vomiting within 1 day after surgery. Planned start May 2026; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
postoperative nausea and vomiting (PONV)postoperative painGastrointestinal Dysmotility
Beyond the preview
Go deeper on ChiCTR2600125309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125309.